(Reuters) – The European Medicines Agency on Friday recommended the use of Johnson & Johnson and its partner Legend Biotech Corp’s therapy to treat multiple myeloma.
The EMA’s recommendation, which needs to be signed off by the European Commission, comes nearly a month after the drug was approved by the U.S. health regulator.
The treatment, Carvykti, belongs to a class of drugs known as CAR-T therapies, or chimeric antigen receptor T-cell therapies.
Legend and J&J plan to sell the drug in Greater China at 70-30 split in profit and a 50-50 split in all other countries.
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
